These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 26490280)

  • 21. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Features of trastuzumab-related cardiac dysfunction: deformation analysis outside left ventricular global longitudinal strain.
    Nhat GM; Hai NH; Duc VT; Tri HHQ; Hoa CN
    Front Cardiovasc Med; 2024; 11():1291180. PubMed ID: 38312233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Artificial intelligence electrocardiogram as a novel screening tool to detect a newly abnormal left ventricular ejection fraction after anthracycline-based cancer therapy.
    Jacobs JEJ; Greason G; Mangold KE; Wildiers H; Willems R; Janssens S; Noseworthy P; Lopez-Jimenez F; Voigt JU; Friedman P; Van Aelst L; Vandenberk B; Attia ZI; Herrmann J
    Eur J Prev Cardiol; 2024 Mar; 31(5):560-566. PubMed ID: 37943680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From 60% to 5% in 12 Weeks: A Trastuzumab-Induced Left Ventricular Ejection Fraction Drop.
    Pan Q; Zhao R; Graham-Hill S
    Cureus; 2024 Apr; 16(4):e59172. PubMed ID: 38707046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab.
    Cao L; Cai G; Chang C; Miao AY; Yu XL; Yang ZZ; Ma JL; Zhang Q; Wu J; Guo XM; Chen JY
    Oncologist; 2015 Jun; 20(6):605-14. PubMed ID: 25933931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management.
    Domercant J; Polin N; Jahangir E
    Ochsner J; 2016; 16(3):250-6. PubMed ID: 27660573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer.
    Battisti NML; Andres MS; Lee KA; Ramalingam S; Nash T; Mappouridou S; Senthivel N; Asavisanu K; Obeid M; Tripodaki ES; Angelis V; Fleming E; Goode EF; John S; Rosen SD; Allen M; Stanway S; Lyon AR; Ring A
    Breast Cancer Res Treat; 2021 Jul; 188(1):149-163. PubMed ID: 33818652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Australia and New Zealand Cardio-Oncology Registry: evaluation of chemotherapy-related cardiotoxicity in a national cohort of paediatric cancer patients.
    Lapirow D; La Gerche A; Toro C; Masango E; Costello B; Porello E; Ludlow L; Marshall G; Trahair T; Mateos M; Lewin J; Byrne J; Boutros R; Manudhane R; Heath J; Ayer J; Gabriel M; Walwyn T; Saundankar J; Forsey J; Le H; Mason K; Celermajer D; Downie P; Walker R; Holland L; Martin M; McLeman L; Diamond Y; Marcocci M; Donath S; Cheung M; Elliott DA; Conyers R
    Intern Med J; 2021 Feb; 51(2):229-234. PubMed ID: 31841257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.
    Hussain Y; Drill E; Dang CT; Liu JE; Steingart RM; Yu AF
    Breast Cancer Res Treat; 2019 May; 175(1):239-246. PubMed ID: 30721443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
    J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a Cardio-Oncology Service in Lithuania: Prediction, Prevention, Monitoring and Treatment of Cancer Treatment-Induced Cardiotoxicity.
    Čiburienė E; Aidietienė S; Ščerbickaitė G; Brasiūnienė B; Drobnienė M; Baltruškevičienė E; Žvirblis T; Čelutkienė J
    J Cardiovasc Dev Dis; 2022 Apr; 9(5):. PubMed ID: 35621845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient reported physical and mental health changes associated with a comprehensive cardiovascular risk reduction program for women with breast cancer receiving potentially cardiotoxic chemotherapy.
    Fradley MG; Alomar M; Kilpatrick MW; Shields B; Tran N; Best A; Bianco E; Armanious M; Vautier RA; Kip K; Beckie TM; Ismail-Khan R
    Cardiooncology; 2021 May; 7(1):22. PubMed ID: 34059163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Permissive Cardiotoxicity: The Clinical Crucible of Cardio-Oncology.
    Porter C; Azam TU; Mohananey D; Kumar R; Chu J; Lenihan D; Dent S; Ganatra S; Beasley GS; Okwuosa T
    JACC CardioOncol; 2022 Sep; 4(3):302-312. PubMed ID: 36213359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?
    Levis BE; Binkley PF; Shapiro CL
    Lancet Oncol; 2017 Aug; 18(8):e445-e456. PubMed ID: 28759384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.
    Rygiel K
    Indian J Pharmacol; 2016; 48(5):490-497. PubMed ID: 27721532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.
    Gulati G; Heck SL; Røsjø H; Ree AH; Hoffmann P; Hagve TA; Norseth J; Gravdehaug B; Steine K; Geisler J; Omland T
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29118031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trastuzumab containing regimens for early breast cancer.
    Moja L; Tagliabue L; Balduzzi S; Parmelli E; Pistotti V; Guarneri V; D'Amico R
    Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD006243. PubMed ID: 22513938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
    Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM
    Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exercise-based cardio-oncology rehabilitation for cardiotoxicity prevention during breast cancer chemotherapy: The ONCORE randomized controlled trial.
    Díaz-Balboa E; Peña-Gil C; Rodríguez-Romero B; Cuesta-Vargas AI; Lado-Baleato O; Martínez-Monzonís A; Pedreira-Pérez M; Palacios-Ozores P; López-López R; González-Juanatey JR; González-Salvado V
    Prog Cardiovasc Dis; 2024; 85():74-81. PubMed ID: 38395212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN).
    Pituskin E; Haykowsky M; McNeely M; Mackey J; Chua N; Paterson I
    BMC Cancer; 2016 Sep; 16(1):733. PubMed ID: 27629548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.